公开(公告)号：US20230203462A1

公开(公告)日：2023-06-29

申请号：US17767426

申请日：2020-10-09

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Zhedfan Yuan ,  Shaoyi Jiang ,  Yanjiao Han ,  Sijin Luozhong

IPC: C12N9/22 ,  C12N15/52 ,  C12N15/113

CPC classification number: C12N9/22 ,  C12N15/52 ,  C12N15/113

Abstract: Provided are compositions and methods for the production of modified endonucleases such as CRISPR/Cas9 system with reduced off-target activity. Methods of editing of polynucleotides using the modified endonucleases in vitro and in vivo are also disclosed. In one aspect, the disclosure provides a modified endonuclease, comprising an endonuclease and one or more mixed charge moieties covalently linked to the endonuclease, wherein each mixed charge moiety comprises about 10 to about 400 positively charged moieties and about 10 to about 400 negatively charged moieties, and wherein the ratio of the number of positively charged moieties to the number of negatively charged moieties is from about 1 :0.5 to about 1 :2.

公开(公告)号：US20210324010A1

公开(公告)日：2021-10-21

申请号：US17283708

申请日：2019-10-10

Applicant: University of Washington

Inventor： Caroline Tsao ,  Sijin Luozhong ,  Trevor Corrigan ,  Shaoyi Jiang ,  Erik Liu ,  Patrick McMullen

IPC: C07K14/00 ,  A61K47/64 ,  C07K14/535 ,  C07K14/56 ,  C07K14/435

Abstract: Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, which results in a better therapeutic efficacy compared to an active protein alone. Thus, a fusion protein or a conjugate of the disclosure can be useful in developing a protein or peptide drug, treating or preventing diseases, disorders, or conditions, or improving a subjects health or wellbeing.